NASDAQ:BIOX - Nasdaq - KYG1117K1141 - Common Stock
TTM (2024-9-30) | 2024 (2024-6-30) | 2023 (2023-6-30) | 2022 (2022-6-30) | 2021 (2021-6-30) | ||||
---|---|---|---|---|---|---|---|---|
Revenue | 441.25M | 464.83M | 415.10M | 328.40M | 206.70M | |||
Minority Interest Expense | -1.30M | -3.01M | -1.39M | -3.30M | -3.00M | |||
Cost Of Goods | 262.41M | 278.22M | 235.46M | 208.40M | 118.60M | |||
Gross Profit | 178.84M | 186.61M | 179.64M | 120.00M | 88.10M | |||
Operating Expenses | 137.76M | 143.40M | 127.26M | 87.60M | 53.50M | |||
Research and Development | N/A | 10.64M | 9.89M | 4.10M | 4.00M | |||
Selling, General, and Administrative Expenses | N/A | 113.51M | 101.87M | 72.80M | 44.40M | |||
Operating Income | 41.08M | 43.20M | 52.37M | 32.40M | 34.60M | |||
Interest Income/Expense | -27.41M | -25.21M | -22.59M | -16.80M | -20.20M | |||
Other Income/Expense | N/A | -7.91M | -11.29M | -7.90M | -6.60M | |||
Non Recurring Items | 243.33K | -45.75K | 610.55K | 6.40M | 2.80M | |||
Income Before Taxes | 5.88M | 10.04M | 19.11M | 14.10M | 10.50M | |||
Income Tax | 2.15M | 3.78M | -1.07M | 18.00M | 14.40M | |||
Net Income | 2.44M | 3.24M | 18.78M | -7.20M | -6.90M | |||
EBITDA | N/A | 64.50M | 71.77M | 41.59M | 40.87M | |||
Per Share Data | ||||||||
EPS Diluted Total Ops | 0.03 | 0.05 | 0.30 | -0.17 | -0.18 | |||
Non GAAP EPS | 0.04 | 0.06 | 0.25 | -0.14 | -0.18 | |||
Statistics | ||||||||
Gross Profit Margin | 40.53% | 40.15% | 43.28% | 36.54% | 42.62% | |||
Profit Margin | 0.55% | 0.70% | 4.52% | -2.19% | -3.34% | |||
Operating Profit Margin | 9.31% | 9.29% | 12.62% | 9.87% | 16.74% |
All data in USD